



Solid Organ Transplant Immunosuppression

**Nicholas Jandovitz, PharmD
Nadine Breslin, PharmD**

Disclosure

- No conflicts of interest

Objectives

- Discuss the purpose and role of immunosuppressive therapy
- Describe the pharmacology, dosing, and adverse effects of medications used in transplant recipients
- Identify important drug interactions involving transplant medications




1. Pathophysiology and Background



2. Types of Immunosuppression:
a) Induction
b) Maintenance



3. Maintenance Immunosuppression



4. Drug-drug interactions

Transplant Immunosuppression


Rejection



Infection


Toxicity

T-cell Activation




Halloran PF et al. *N Engl J Med* 2004;351:2715-29.


Immunosuppression Timeline



Death Censored Graft Failure



10 Year Mortality in Kidney Transplant



Induction vs. Maintenance Immunosuppression

Induction

High dose, short term immunosuppression given pre- and peri-transplant

Reduces acute rejection

Delays the onset of maintenance immunosuppressants




Maintenance

Low dose, long term immunosuppression given post-transplant

Prevents acute and chronic rejection



Immunosuppression Regimen



Immunosuppression Goal



Net State of Immunosuppression

Least immunogenic

- Lowest degree of immunosuppression

Most immunogenic

- Highest degree of immunosuppression



Induction Therapy

High dose corticosteroids

Basiliximab

Anti-thymocyte globulin

Alemtuzumab

Corticosteroids

Mechanism of Action	Dose dependent inhibition of immune response Suppresses IL-1,2,3,6, gamma interferon, TNF-alpha, platelet activating factor, prostaglandins, leukotrienes and TNF
Target	Antigen Presenting Cells (APCs)
Dosing	500 – 1000 mg given intra-operatively and then tapered

Corticosteroids: Adverse Effects

Acute Changes

Hyperglycemia
Leukocytosis
Impaired wound healing
GI disturbance
CNS effects (euphoria, depression, insomnia)

Chronic Changes

Weight gain
Osteoporosis, avascular necrosis
Fluid retention / hypertension
Hyperlipidemia
Cataracts / glaucoma
Growth retardation
Acne
Hirsutism
Infection

Antibody Agents

Lymphocyte depleting	Polyclonal	Anti-thymocyte globulin (Thymoglobulin [®] , Atgam [®])
	Monoclonal	Alemtuzumab (Campath [®])

Non- lymphocyte depleting	Monoclonal	Basiliximab (Simulect [®])
--	------------	--------------------------------------

Anti-thymocyte Globulin

- Cytotoxic antibodies directed against human T-lymphocytes

Rabbit-derived (rATG):

Thymoglobulin[®]



Thymoglobulin[®] > Atgam[®]

- Greater potency
- Better tolerated

Horse-derived: Atgam[®]



Anti-thymocyte Globulin

Mechanism of Action	Antibodies specific for lymphocyte surface markers CD2,3,4,8,16,25,45 Opsonize platelets, lymphoid, and PMN cells
Target	T and B cells, dendritic cells, plasma cells, NK cells, adhesion molecules
Adverse Effects	Thrombocytopenia, leukopenia, cytokine-release syndrome, infection, malignancy, flash pulmonary edema, allergic reactions, serum sickness
Cost	~ \$800/ vial (25 mg)
Duration	Lymphocyte depletion: 24 hours Duration: 6 – 12 months

rATG Dosing and Administration

- Typical Dosing: 1.5 mg/kg/day for 4 doses
 - Round dose to nearest 25 mg
 - Typical maximum daily dose: 150 mg
- Pre-medications: acetaminophen, diphenhydramine, corticosteroid
- Infuse over at least 6 hours through a 0.22 micron filter

Laboratory Parameter

Dose Adjustment

WBC >3 or ANC \geq 1.5 or Platelets >75,000

No change

WBC 2–3 or ANC 1–1.4 or Platelets 50,000–75,000

Decrease by 50%

WBC <2 or ANC <1 or Platelets <50,000

Hold


WBC: White blood cell;
ANC: absolute neutrophil count

Alemtuzumab (Campath®)

Mechanism	Monoclonal antibody against CD52 that triggers antibody-dependent cytotoxicity and lysis
Target	B and T cells, macrophages, NK cells, some granulocytes
Dose	30 mg IV infusion (central or peripheral) over 2 hours x 1 dose Pre-medications: acetaminophen, diphenhydramine, steroids
Adverse Events	Cytokine release syndrome, rash, myelosuppression, infection, malignancy, infusion reaction
Duration	12 months

Basiliximab

Mechanism of Action	Chimeric monoclonal anti IL-2 receptor antibody (CD 25) Non-depleting
Target	Activated T-cells only
Dosing	20 mg IV infusion over 30 minutes on POD 0 and POD 4 Does not require pre-medications
Adverse Effects	Infection, malignancy, hypersensitivity
Cost	~ \$3500/vial (20 mg)
Duration	2-4 weeks



Assessment Question

Horton is a 45 year old male s/p deceased donor renal transplant receiving his fourth and final dose of anti-thymocyte globulin (ATG) 125 mg for induction therapy


Wt: 80 kg

WBC: 1.9

Platelets: 102

What dose of ATG should Horton receive?

- A. Horton should not receive any ATG
- B. Horton should receive 75 mg of ATG
- C. Horton should receive 125 mg of ATG
- D. The maximum daily dose of ATG is 100 mg, so Horton should only receive 100 mg



Choosing an Induction Agent

Induction agent

No induction < Basiliximab < Alemtuzumab < Anti-thymocyte globulin



Lower risk

Zero HLA mismatch
Live donor
Caucasian ethnicity
Low panel reactive antibody
Absence of donor specific antibody
Blood group compatibility
Immediate graft function
Short cold ischemia time
First transplant

Higher risk

Increased # of HLA mismatches
Younger recipient and older donor age
African-American ethnicity
High panel reactive antibody
Presence of donor specific antibody
Blood group incompatibility
Delayed onset of graft function
Long cold ischemia time
Retransplant

Maintenance Therapy



Maintenance therapy



Calcineurin Inhibitors (CNI)

- Cyclosporine
- Tacrolimus



Anti-metabolites

- Azathioprine
- Mycophenolate



Mammalian target of rapamycin (mTOR) inhibitors

- Sirolimus
- Everolimus



CD80/86 Inhibitor

- Belatacept





Corticosteroids

- Methylprednisolone
- Prednisone

Calcineurin Inhibitors

- Tacrolimus (FK) and Cyclosporine (CsA)
- Backbone of maintenance immunosuppressive regimen
- Therapeutic trough monitoring
 - Organ transplanted
 - Time since transplant
 - Concomitant immunosuppression
 - Adverse effects



Tacrolimus and Cyclosporine



Prograf®

Immediate release
Twice daily dosing


0.5, 1, 5 mg capsules
1 mg/mL suspension



Astagraf®

Extended release
Once daily dosing

0.5, 1, 5 mg capsules



Envarsus®

Extended release
Once daily dosing

0.75, 1, 4 mg tablets



Sandimmune®

Erratic absorption
Twice daily dosing

25, 100 mg capsules
100 mg/mL solution



Neoral®*

Microemulsion
Better absorption
Twice daily dosing

25, 100 mg capsules
100 mg/mL solution




Gengraf®

Microemulsion
Better absorption
Twice daily dosing



25, 50, 100 mg capsules
100 mg/mL solution

Sandimmune ≠ Neoral, Gengraf

Prograf® [package insert]. Northbrook, IL: Astellas Pharma US, Inc.; 2015.; Astagraf® [package insert]. Northbrook, IL: Astellas Pharma US, Inc.; 2015.; Envarsus® [package insert]. Cary, North Carolina: Veloxis Pharmaceuticals, Inc.; 2017.; Neoral® [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation.; 2015. Sandimmune® [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation.; 2015. Gengraf® [package insert]. North Chicago, IL: AbbVie Inc.; 2015.




Tacrolimus: Converting between Formulations



Prograf[®] [package insert]. Northbrook, IL: Astellas Pharma US, Inc.; 2015.
Astagraf[®] [package insert]. Northbrook, IL: Astellas Pharma US, Inc.; 2015.
Envarsus[®] [package insert]. Cary, North Carolina: Veloxis Pharmaceuticals, Inc.; 2017.
van Hooff J, Van der Walt I, Kallmeyer J, et al. *Ther Drug Monit.* 2012;34:46–52.
Alloway R, Steinberg S, Khalil K, et al. *Transplant Proc.* 2005;37:867–870.

CNI: Formulations and Dose Conversions

Formulation		Tacrolimus IR (Prograf®)	Cyclosporine
Suspension	Preparation	1 mg/mL	100 mg/mL
	Dose Conversion	1:1	1:1
Intravenous (IV)	Administration	Administer as a continuous infusion over 24 hours to minimize nephrotoxic effects	
	Dose Conversion	Calculate IV tacrolimus by taking one-fifth of the total daily oral dose	Calculate IV cyclosporine by taking one-third of the total daily oral dose
Sublingual (SL)	Administration	Only use tacrolimus capsules for SL administration. Oral suspension should not be used for SL administration	Not Applicable
	Dose Conversion	Oral → SL = 50% of tacrolimus dose SL → oral = tacrolimus dose is doubled	




CNI Pharmacokinetics

- **Absorption:** small intestine
- **Distribution:** highly protein bound (99%) and binds to RBCs
- **Metabolism:** CYP3A4 (liver and intestine) and P-glycoprotein (intestine)
- **Excretion:** bile




Prograf® [package insert]. Northbrook, IL: Astellas Pharma US, Inc.; 2015.; Envarsus® [package insert]. Cary, North Carolina: Veloxis Pharmaceuticals, Inc.; 2017.; Neoral® [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation.; 2015.



CNI Adverse Effects

Adverse Effects	CsA	FK
Hypertension	++	+
Hyperlipidemia	++	+
New-onset diabetes	+	++
Electrolyte abnormalities Hyperkalemia, hypomagnesemia, hypophosphatemia	+	+
Nephrotoxicity	++	++
Neurotoxicity	+	++
Alopecia		+
Gingival Hyperplasia	+	
Hirsutism	+	



Assessment Question

Which of the following formulations of tacrolimus are dosed once daily?

- A. Prograf[®]
- B. Astagraf[®]
- C. Envarsus[®]
- D. A and B
- E. B and C
- F. All of the above

Anti-metabolites

Mycophenolate mofetil (CellCept®)

- Twice daily dosing
- 250 mg capsules, 500 mg tablets
- Suspension: 200 mg/mL
- IV to PO is 1:1 conversion

1000 mg twice daily

500 mg twice daily



Mycophenolic Sodium (Myfortic®)

- Twice daily dosing
- 180, 360 mg tablets
- Enteric-coated sodium salt

720 mg twice daily

360 mg twice daily


Azathioprine (Imuran®)

- Once daily dosing
- 50 mg tablet (Can be cut in half)
- 1 – 3 mg/kg/day



Cellcept [package insert]. San Francisco, CA: Genentech Inc; 2015.; Myfortic [package insert]. East Hanover, NJ: Novartis; 2016.; Imuran [package insert]. San Diego, CA: Prometheus Laboratories Inc; 2014

Mycophenolic Acid (MPA): Mechanism of Action



MPA inhibits inosine monophosphate dehydrogenase (IMPDH)



IMPDH is responsible for *de novo* purine synthesis and DNA synthesis in T and B cells




Lymphocytes cannot utilize salvage pathways to make DNA



MPA: Pharmacokinetics


- Absorption → ~90%
 - Non-linear PK
- Distribution → 99% plasma protein bound
- Metabolism → conjugation in the liver
 - Major metabolite (MPAG)- enterohepatic recycling
 - Minor metabolite (AcMPAG)
- Excretion → metabolites excreted into urine



Cellcept [package insert]. San Francisco, CA: Genentech Inc; 2015.; Myfortic [package insert]. East Hanover, NJ: Novartis; 2016.

Azathioprine (Imuran[®])

- Prodrug and derivative of 6-mercaptopurine (6-MP)
- Mechanism of action
 - Purine mimetic antimetabolite
 - Resembles guanosine purine
 - Inhibit DNA synthesis to decrease circulating T and B cells




Maltzman JS, Koretzky GA. *J Clin Invest.* 2003;111(8):1122-4.

Anti-metabolites: Adverse Effects

Adverse Effects	MPA	AZA
Gastrointestinal (N/V/D)	++	
Leukopenia	++	+/-
Thrombocytopenia	++	+/-
Teratogenic	+	
Hepatotoxicity		+



mTOR Inhibitors: Mechanism



Molecular

- Inhibit DNA synthesis at G1 to S phase progression

Biological

- Down regulation of: T cells, B cells, Endothelial cells, smooth muscle cells

Clinical

- Decrease acute rejection
- Decrease chronic allograft nephropathy
- Decrease wound healing
- Anti-cancer effects



Image created by Demetra Tsapepas

Mammalian target of rapamycin (mTOR) inhibitors

	Sirolimus	Everolimus
Dose	2-15 mg PO once daily	0.75 mg PO twice daily
Dosage forms	0.5, 1, and 2 mg tablets 1 mg/mL oral solution	0.25, 0.5, 0.75 mg tablets
Metabolism	CYP 3A3/4	CYP 3A3/4
Excretion	91% feces, 2.2% urine	80% feces, 5% urine
Half life	62 hours	30 hours
Trough 5-7 days	3-8 ng/mL*	

*Target concentrations will vary depending on organ transplanted, time since transplant, concomitant immunosuppressive and other medications, assay used, side effects experienced



Zortress (everolimus) [product information]. Novartis 2015.; Rapamycin (sirolimus) [product information]. Pfizer 2015.

Niche in SOT

Differing
adverse
effects

Anti-viral
properties

Anti-fibrotic
properties

Anti-
proliferative
properties



mTOR Inhibitors Adverse Effects


Adverse Effects	mTOR
Dyslipidemia	++
Mouth Ulcers	++
Pulmonary toxicity	+
Wound complications	+
Nephrotic syndrome (proteinuria)	+



Rapamycin (sirolimus) [product information]. Pfizer 2015.; Zortress (everolimus) [product information]. Novartis 2015.

Belatacept

- Fusion protein
- Co-stimulation antagonist at CD80 and CD86 receptors on APCs
- Inhibition of T-cell activation and proliferation
- Inhibits production of cytokines interleukin-2, interferon- γ , interleukin-4, and TNF- α



Nulojix (belatacept) [product information]. Bristol-Myers Squibb 2016.

Belatacept

- Approved in kidney transplantation
- Use in EBV seropositive patients **ONLY**
- No dose adjustments for renal or hepatic dysfunction
- No therapeutic drug monitoring



Nulojix (belatacept) [product information]. Bristol-Myers Squibb 2016.

Dosing

Initial Phase (10 mg/kg)

- Day 1 (day of transplantation)
- Day 5
- End of Week 2, 4, 8, and 12

Maintenance Phase (5 mg/kg)

- End of Week 16
- Every 4 weeks

Administered over 30 minutes

No pre-medications required


Dose based on actual body weight

Doses must be divisible by 12.5




Nulojix (belatacept) [product information]. Bristol-Myers Squibb 2016.

Black Box Warnings and Adverse Effects



PTLD




Increased risk of graft loss and death in liver transplant




Peripheral edema


Niche in SOT



Maintenance therapy



Drug-Drug interactions



CYP3A4/PGP Inducers

Drug	Mechanism of interaction	Effect on CNI levels	Effect on mTOR levels	Management	
Anti-epileptics: Phenytoin Phenobarbital Carbamazepine	Induce CYP3A4	↓	↓	Double CNI dose Monitor levels Monitor levels	
Rifamycins Rifampin Rifabutin		(INCREASE metabolism)	↓↓↓ ↓	↓↓↓ ↓	Double CNI mTOR: alternative therapy Monitor levels
St. John's wort		↓	↓	Avoid therapy	

Glantzbecker B, Duncan C, Alyea E, et al. *Biol Blood Marrow Transplant.* 2012;18(7):989-1006. Manitpisitkul W, Mccann E, Lee S, Weir MR. *Curr Opin Nephrol Hypertens.* 2009;18(5):404-11.

CYP3A4/PGP Inhibitors

Drug	Mechanism of interaction	Effect on CNI levels	Effect on mTOR levels	Management
Azole antifungals	Inhibit CYP3A4 (DECREASE metabolism)			
Clotrimazole		↑	↑	↓
Fluconazole		↑	↑	↓
Isavuconazole		↑	↑	↓
Posaconazole		↑↑	↑↑	↓
Voriconazole		↑↑	↑↑	↓
CCB Diltiazem& Verapamil		↑	↑	↓ CNI 25- 50%
Macrolides Erythromycin Clarithromycin		↑ ↑	↑ ↑	↓CNI 50-75% ↓CNI 50-75%
Protease inhibitors Ritonavir Darunavir		↑↑↑	↑↑↑	Dose by level
Amiodarone		↑	↑	↓CNI 50%
Cobicistat	↑↑↑	↑↑↑	Dose by level	

Glantzbecker B, Duncan C, Alyea E, Campbell B, Soiffer R. *Biol Blood Marrow Transplant.* 2012;18(7):989-1006. Manitpisitkul W, Mccann E, Lee S, Weir MR. *Curr Opin Nephrol Hypertens.* 2009;18(5):404-11.

Azole Antifungal Agents

Drug	Degree of CYP3A4 Inhibition	PK $T_{1/2}$	Dose reductions	
			CNI	mTOR
Fluconazole	++	30 hours	↓ 25-50%	↓ 50-70%
Isavuconazole	++	130 hours	↓ ? Monitor levels	↓ 50-70% Monitor levels
Voriconazole	+++	Variable, dose-dependent	↓ 66-75%	↓ 90% Avoid
Posaconazole	+++	~30-35 hours	↓ 66-75%	↓ 90% Avoid

Trofe-clark J, Lemonovich TL. *Am J Transplant.* 2013;13 Suppl 4:318-26 .; Glotzbecker B, Duncan C, Alyea E, Campbell B, Soiffer R. *Biol Blood Marrow Transplant.* 2012;18(7):989-1006.; Dodds-ashley E. *Pharmacotherapy.* 2010;30(8):842-54

Assessment Question

The Grinch is a 42 year old male s/p heart transplant on maintenance immunosuppression with tacrolimus 6 mg twice daily, mycophenolate mofetil 1,000 mg twice daily, and prednisone 10 mg daily. The team would like to start therapy with voriconazole for *aspergillus*.

How would you dose adjust his medications?

- A. No dose adjustments are necessary
- B. Reduce mycophenolate mofetil to 500 mg twice daily
- C. Increase tacrolimus to 8 mg twice daily
- D. Decrease tacrolimus to 2 mg twice daily
- E. Dose tacrolimus by levels




Azathioprine and Xanthine Oxidase (XO) Inhibitors



Severe myelosuppression



Reduce azathioprine dose by 50 - 75%
Avoid combination if possible



Maltzman JS, Koretzky GA. *J Clin Invest.* 2003;111(8):1122-4. Manitpisitkul W, Mccann E, Lee S, Weir MR. *Curr Opin Nephrol Hypertens.* 2009;18(5):404-11.

Pharmacodynamic Interactions

Nephrotoxicity

- NSAIDs (ibuprofen, naproxen, ketorolac)
- ACE-i/ARB (lisinopril, losartan)
- Aminoglycosides (gentamicin, tobramycin)

QT prolongation

- Antipsychotics (quetiapine, haloperidol, olanzapine)
- Antifungals (fluconazole, voriconazole, posaconazole)
- Fluoroquinolones (levofloxacin, ciprofloxacin)


Hyperkalemia

- ACE-i/ARB (lisinopril, losartan)
- Potassium-sparing diuretics (spironolactone, triamterene)

Leukopenias and thrombocytopenias

- Anti-thymocyte globulin
- Linezolid
- Valganciclovir/Ganciclovir

Transplantation is a **Balancing Act**



Conclusion

- Immunosuppression is essential in organ transplant recipients
- Immunosuppression should be individualized to optimize medical management and minimize adverse reactions
- Adjusting dosing of medications for drug interactions is multifactorial



Solid Organ Transplant Immunosuppression

**Nicholas Jandovitz, PharmD
Nadine Breslin, PharmD**